Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

被引:545
作者
Guidos, Robert J.
Spellberg, Brad
Blaser, Martin
Boucher, Helen W.
Bradley, John S.
Eisenstein, Barry I.
Gerding, Dale
Lynfield, Ruth
Reller, L. Barth
Rex, John
Schwartz, David
Septimus, Edward
Tenover, Fred C.
Gilbert, David N.
机构
[1] Arlington, VA 22209
关键词
INFECTIOUS-DISEASES SOCIETY; STAPHYLOCOCCUS-AUREUS INFECTIONS; VENTILATOR-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; HEALTH-CARE EPIDEMIOLOGY; BLOOD-STREAM INFECTIONS; GRAM-NEGATIVE BACTERIA; FUTURE CLINICAL-TRIALS; UNITED-STATES; RISK-FACTORS;
D O I
10.1093/cid/cir153
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antimicrobial resistance is recognized as one of the greatest threats to human health worldwide [1]. Drugresistant infections take a staggering toll in the United States (US) and across the globe. Just one organism, methicillin-resistant Staphylococcus aureus (MRSA), kills more Americans every year (∼19,000) than emphysema, HIV/AIDS, Parkinson's disease, and homicide combined [2]. Almost 2 million Americans per year develop hospital-acquired infections (HAIs), resulting in 99,000 deaths [3], the vast majority of which are due to antibacterial (antibiotic)-resistant pathogens. Indeed, two common HAIs alone (sepsis and pneumonia) killed nearly 50,000 Americans and cost the US health care systemmore than $8 billion in 2006 [4]. In a recent survey, approximately half of patients in more than 1,000 intensive care units in 75 countries suffered from an infection, and infected patients had twice the risk of dying in the hospital as uninfected patients [5]. Based on studies of the costs of infections caused by antibiotic-resistant pathogens versus antibiotic-susceptible pathogens [6-8], the annual cost to the US health care system of antibioticresistant infections is $21 billion to $ 34 billion and more than 8 million additional hospital days. © 2011 The Author.
引用
收藏
页码:S397 / S428
页数:32
相关论文
共 126 条
[71]   Methicillin-resistant S-aureus infections among patients in the emergency department [J].
Moran, Gregory J. ;
Krishnadasan, Anusha ;
Gorwitz, Rachel J. ;
Fosheim, Gregory E. ;
McDougal, Linda K. ;
Carey, Roberta B. ;
Talan, David A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :666-674
[72]   Urinary tract infection caused by fluoroquinolone- and cepherm-resistant Enterobacteriaceae [J].
Muratani, Tetsuro ;
Matsumoto, Tetsuro .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 28 :S10-S13
[73]  
Northey ElmoreH., 1948, SULFONAMIDES ALLIED
[74]   Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea [J].
Park, Young Kyoung ;
Jung, Sook-In ;
Park, Kyong-Hwa ;
Cheong, Hae Suk ;
Peck, Kyong Ran ;
Song, Jae-Hoon ;
Ko, Kwan Soo .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2009, 64 (01) :43-51
[75]   Resistance in gram-negative bacteria: Enterobacteriaceae [J].
Paterson, David L. .
AMERICAN JOURNAL OF INFECTION CONTROL, 2006, 34 (05) :S20-S28
[76]   The research agenda of the National Institute of Allergy and Infectious Diseases for antimicrobial resistance [J].
Peters, N. Kent ;
Dixon, Dennis M. ;
Holland, Steven M. ;
Fauci, Anthony S. .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) :1087-1093
[77]   The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents [J].
Powers, JH ;
Ross, DB ;
Brittain, E ;
Albrecht, R ;
Goldberger, MJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (06) :879-881
[78]   Noninferiority and equivalence trials: deciphering 'similarity' of medical interventions [J].
Powers, John H. .
STATISTICS IN MEDICINE, 2008, 27 (03) :343-352
[79]   Antibacterial drug discovery: is it all downhill from here? [J].
Projan, SJ ;
Shlaes, DM .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 :18-22
[80]   Why is big Pharma getting out of antibacterial drug discovery? [J].
Projan, SJ .
CURRENT OPINION IN MICROBIOLOGY, 2003, 6 (05) :427-430